Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14015-14028

  Alonso, Florian ^a   Domingos Pereira, Sonia ^a   Gal, Loïc Le ^a   Derré, Laurent ^a   Meda, Paolo ^b   Jichlinski, Patrice ^a   Nardelli Haefliger, Denise ^a   Haefliger, Jacques Antoine ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Angiogenesis; Cell cell communication; Connexins; Transgenic mice; Tumors

Indexed keywords

ANGIOPOIETIN RECEPTOR; CONNEXIN 40; CYCLOPHOSPHAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAP27 PEPTIDE[40]; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; GAP JUNCTION PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMOOTH MUSCLE CELL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; APOPTOSIS; BLOOD VESSEL; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERFUSION; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR INVASION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; AORTA; APOPTOSIS; BIOMARKERS, TUMOR; BLOOD VESSELS; CELL PROLIFERATION; CONNEXINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84971642387     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7370     Document Type: Article

References (54)

1. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91: 1071-121.
2. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009; 16: 196-208.
3. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7: 359-71.
4. Bir SC, Xiong Y, Kevil CG, Luo J. Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovascular research. 2012; 95: 7-18.
5. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. The lancet oncology. 2013; 14: 125-33.
6. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012; 72: 1909-14.
7. Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2013; 338: 219-28.
8. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66: 605-12.
9. Bosco D, Haefliger JA, Meda P. Connexins: key mediators of endocrine function. Physiol Rev. 2011; 91: 1393-445.
10. Meens MJ, Kwak BR, Duffy HS. Role of connexins and pannexins in cardiovascular physiology. Cell Mol Life Sci. 2015; 72: 2779-92.
11. Meens MJ, Pfenniger A, Kwak BR, Delmar M. Regulation of cardiovascular connexins by mechanical forces and junctions. Cardiovascular research. 2013; 99: 304-14.
12. Pfenniger A, Wohlwend A, Kwak BR. Mutations in connexin genes and disease. Eur J Clin Invest. 2011; 41: 103-16.
13. Jobs A, Schmidt K, Schmidt VJ, Lubkemeier I, van Veen TA, Kurtz A, Willecke K, de Wit C. Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension. Hypertension. 2012; 60: 1422-9.
14. Simon AM, McWhorter AR. Decreased intercellular dye-transfer and downregulation of non-ablated connexins in aortic endothelium deficient in connexin37 or connexin40. J Cell Sci. 2003; 116: 2223-36.
15. Alonso F, Boittin FX, Beny JL, Haefliger JA. Loss of connexin40 is associated with decreased endothelium-dependent relaxations and eNOS levels in the mouse aorta. Am J Physiol Heart Circ Physiol. 2010; 299: H1365-73.
16. Boittin FX, Alonso F, Le Gal L, Allagnat F, Beny JL, Haefliger JA. Connexins and M3muscarinic receptors contribute to heterogeneous Ca(2+) signaling in mouse aortic endothelium. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013; 31: 166-78.
17. Krattinger N, Capponi A, Mazzolai L, Aubert JF, Caille D, Nicod P, Waeber G, Meda P, Haefliger JA. Connexin40 regulates renin production and blood pressure. Kidney international. 2007; 72: 814-22.
18. Kurtz L, Schweda F, de Wit C, Kriz W, Witzgall R, Warth R,Sauter A, Kurtz A, Wagner C. Lack of connexin 40 causes displacement of renin-producing cells from afferent arterioles to the extraglomerular mesangium. J Am Soc Nephrol. 2007; 18: 1103-11.
19. Wagner C, de Wit C, Kurtz L, Grunberger C, Kurtz A, Schweda F. Connexin40 is essential for the pressure control of renin synthesis and secretion. Circulation research. 2007; 100: 556-63.
20. Kirchhoff S, Kim JS, Hagendorff A, Thonnissen E, Kruger O, Lamers WH, Willecke K. Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice. Circulation research. 2000; 87: 399-405.
21. Le Gal L, Alonso F, Wagner C, Germain S, Nardelli Haefliger D, Meda P, Haefliger JA. Restoration of connexin 40 (Cx40) in Renin-producing cells reduces the hypertension of Cx40null mice. Hypertension. 2014; 63: 1198-204.
22. Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol. 1999; 520 Pt 2:539-50.
23. Vaiyapuri S, Moraes LA, Sage T, Ali MS, Lewis KR, Mahaut-Smith MP, Oviedo-Orta E, Simon AM, Gibbins JM. Connexin40regulates platelet function. Nature communications. 2013; 4: 2564.
24. Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: an update. J Hum Hypertens. 2009; 23: 773-82.
25. Bol M, Van Geyt C, Baert S, Decrock E, Wang N, De Bock M, Gadicherla AK, Randon C, Evans WH, Beele H, Cornelissen R, Leybaert L. Inhibiting connexin channels protects against cryopreservation-induced cell death in human blood vessels. Eur J Vasc Endovasc Surg. 2013; 45: 382-90.
26. Chevalier F, Lavergne M, Negroni E, Ferratge S, Carpentier G,Gilbert-Sirieix M, Sineriz F, Uzan G, Albanese P. Glycosaminoglycan mimetic improves enrichment and cell functions of human endothelial progenitor cell colonies. Stem Cell Res. 2014; 12: 703-15.
27. Gartner C, Ziegelhoffer B, Kostelka M, Stepan H, Mohr FW, Dhein S. Knock-down of endothelial connexins impairs angiogenesis. Pharmacological research. 2012; 65: 347-57.
28. Walther S, Pluteanu F, Renz S, Nikonova Y, Maxwell JT, Yang LZ, Schmidt K, Edwards JN, Wakula P, Groschner K, Maier LS, Spiess J, Blatter LA, et al. Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt- and PKA-mediated phosphorylation of eNOS at serine 1177. Am J Physiol Heart Circ Physiol. 2014; 307: H689-700.
29. Liu S, Premont RT, Rockey DC. Endothelial nitric-oxide synthase (eNOS) is activated through G-protein-coupled receptor kinase-interacting protein 1 (GIT1) tyrosine phosphorylation and Src protein. J Biol Chem. 2014; 289: 18163-74.
30. Lei J, Vodovotz Y, Tzeng E, Billiar TR. Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide. 2013; 35: 175-85.
31. Priya MK, Sahu G, Soto-Pantoja DR, Goldy N, Sundaresan AM, Jadhav V, Barathkumar TR, Saran U, Jaffar Ali BM, Roberts DD, Bera AK, Chatterjee S. Tipping off endothelial tubes: nitric oxide drives tip cells. Angiogenesis. 2015; 18: 175-89.
32. Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001; 276: 32663-9.
33. Looft-Wilson RC, Billaud M, Johnstone SR, Straub AC, Isakson BE. Interaction between nitric oxide signaling and gap junctions: effects on vascular function. Biochimica et biophysica acta. 2012; 1818: 1895-902.
34. Smith TD, Mohankumar A, Minogue PJ, Beyer EC, Berthoud VM, Koval M. Cytoplasmic amino acids within the membrane interface region influence connexin oligomerization. J Membr Biol. 2012; 245: 221-30.
35. Alonso F, Krattinger N, Mazzolai L, Simon A, WaeberG, Meda P, Haefliger JA. An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovascular research. 2010; 87: 166-76.
36. Fang JS, Angelov SN, Simon AM, Burt JM. Cx40 is required for, and cx37limits, postischemic hindlimb perfusion, survival and recovery. J Vasc Res. 2012; 49: 2-12.
37. Figueroa XF, Poblete I, Fernandez R, Pedemonte C, Cortes V, Huidobro-Toro JP. NO production and eNOS phosphorylation induced by epinephrine through the activation of beta-adrenoceptors. Am J Physiol Heart Circ Physiol. 2009; 297: H134-43.
38. Kameritsch P, Pogoda K, Ritter A, Munzing S, Pohl U. Gap junctional communication controls the overall endothelial calcium response to vasoactive agonists. Cardiovascular research. 2012; 93: 508-15.
39. Pepper MS, Meda P. Basic fibroblast growth factor increases junctional communication and connexin 43 expression in microvascular endothelial cells. J Cell Physiol. 1992; 153: 196-205.
40. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011; 12: 551-64.
41. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2010; 180: 103-14.
42. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragones J, et al. Heterozygous deficiency of PHD2restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136: 839-51.
43. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
44. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10: 417-27.
45. Zhang J, O'Carroll SJ, Henare K, Ching LM, Ormonde S, Nicholson LF, Danesh-Meyer HV, Green CR. Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy. FEBS Lett. 2014.
46. Willecke K, Eiberger J, Degen J, Eckardt D, RomualdiA, Guldenagel M, Guldenagel M, Deutsch U, Sohl G. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem. 2002; 383: 725-37.
47. Kirchhoff S, Nelles E, Hagendorff A, Kruger O, Traub O, Willecke K. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol. 1998; 8: 299-302.
48. Le Gal L, Alonso F, Mazzolai L, Meda P, Haefliger JA. Interplay between connexin40 and nitric oxide signaling during hypertension. Hypertension. 2015; 65: 910-5.
49. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56: 21-6.
50. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188: 277-86.
51. Domingos-Pereira S, Derre L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, Nardelli-Haefliger D. Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. J Urol. 2014; 191: 814-22.
52. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer immunology, immunotherapy. 2013; 62: 171-82.
53. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nature protocols. 2012; 7: 89-104.
54. Chen JX, Zeng H, Tuo QH, Yu H, Meyrick B, Aschner JL. NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol. 2007; 292: H1664-74.